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Abstract
In the search for a cure for HIV-1 infection, histone deacetylase inhibitors (HDACi) are
being investigated as activators of latently infected CD4 T cells to promote their targeting
by cytotoxic T-lymphocytes (CTL). However, HDACi may also inhibit CTL function, sug-
gesting different immunotherapy approaches may need to be explored. Here, we study the
impact of different HDACi on both Natural Killer (NK) and CTL targeting of HIV-1 infected
cells. We found HDACi down-regulated HLA class I expression independently of HIV-1 Nef
which, without significantly compromising CTL function, led to enhanced targeting by NK
cells. HDACi-treated HIV-1-infected CD4 T cells were also more effectively cleared than
untreated controls during NK co-culture. However, HDACi impaired NK function, reducing
degranulation and killing capacity. Depending on the HDACi and dose, this impairment
could counteract the benefit gained by treating infected target cells. These data suggest
that following HDACi-induced HLA class I down-regulation NK cells kill HIV-1-infected
cells, although HDACi-mediated NK cell inhibition may negate this effect. Our data empha-
size the importance of studying the effects of potential interventions on both targets and
effectors.
Author Summary
Antiretroviral therapy successfully controls HIV-1 viraemia and can restore life expec-
tancy to within normal limits. However, antiretroviral therapy is not a cure as HIV-1
persists in a treatment-resistant latent reservoir. Therapy also comes with a high cost,
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side effects, and a lifetime commitment to pills. Therefore, there is growing interest in
finding a cure. One proposed strategy is to use novel agents to stimulate HIV-1 tran-
scription in latently-infected cells, after which the cells could be targeted and cleared by
the immune system. Of current interest are the latency-reversing histone deacetylase
inhibitors (HDACi), with CD8 T cells and NK cells potentially serving as the HIV-1 kill-
ing agents. However, previous studies suggested HDACi negatively affected CD8 T cell
function, compromising their role as killers. Here we studied whether NK cells might
serve as effective killers of HDACi treated CD4 T cells, especially as HDACi may induce
HLA class I down-regulation. We found that although treating infected cells with
HDACi resulted in HLA class I down-regulation and enhanced their visibility to NK
cells, HDACi inhibited NK cell function overall, suggesting additional killing strategies
will be required.
Introduction
Antiretroviral therapy (ART) is capable of controlling viraemia in HIV-1-infected individuals
to undetectable levels. However, ART is not a cure. A pool of latently infected cells persists,
despite therapy, for the lifetime of the individual. One approach to target this latent reservoir is
to activate latently-infected cells to stimulate virus production followed by cytopathic,
immune-mediated, or other interventions to induce the death of the infected cells, a strategy
that has been called ‘shock and kill’ [1].
One drug class being explored to activate HIV-1 transcription is histone deacetylase inhibi-
tors (HDACi) that include vorinostat (SAHA), romidepsin, and panobinostat. These drugs can
induce HIV-1 expression without globally activating the immune system [2], and in clinical tri-
als have resulted in increased levels of unspliced cell associated HIV-1 RNA [3, 4] and
increased viraemia [5].
However, HIV-1 expression alone may not be sufficient for viral clearance as infected cells
may persist despite producing HIV-1 proteins [6]. Therefore an additional ‘kill’ strategy will
be required for successful clearance of infected cells. Although CD8+ve cytotoxic T cells
(CTL) kill HIV-1-infected cells and are the most likely effectors in ‘shock and kill,’HDACi
may inhibit the CTL response [7]. Additionally, HDACi can also induce HLA class I down-
regulation, potentially impairing antigen presentation to CTL. For example, HDACi may
induce HIV-1 Nef expression which would subsequently lead to HLA class I down-regulation
[8], or HDACi may directly affect HLA class I levels independently of Nef as has been found
in several cell lines [9–11]. Unless this can be addressed, these data suggest that the CTL
response may not be sufficient for killing cells after HDACi-induced HIV-1 expression. Natu-
ral killer (NK) cells also clear infected cells, particularly when HLA class I expression is
reduced, and so theoretically may provide an alternative approach to eliminating cells stimu-
lated from latency by HDACi.
Here, we show that the HDACi vorinostat, panobinostat, and romidepsin down-regulate
HLA class I levels ex vivo independently of HIV-1 Nef to levels sufficient to lead to NK cell
degranulation, even without HIV-1 infection. HDACi treatment of infected cells also led to
increased NK cell mediated clearance. However, NK cell function was inhibited following treat-
ment with HDACi, indicating that the negative effects of HDACi on NK cells will need to be
addressed before NK cells can be used as effective agents of reservoir clearance in clinical trials.
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Results
HDACi down-regulate HLA class I in primary CD4 T cells independently
of Nef
We first examined the impact of HDACi on HLA class I in uninfected primary CD4 T cells (as
cell lines may not accurately reflect in vivo effects). We initially cultured uninfected CD4 T
cells for 24 hours in the presence of 1μM vorinostat, 100nM panobinostat, or 10nM romidep-
sin. All three HDACi significantly lowered HLA class I expression in uninfected CD4 T cells
compared to untreated controls. The MFI (mean+/- S.D.) for untreated cells was 8464 +/-4797,
compared with vorinostat 5851 +/- 4587 (p = 0.04), panobinostat 5724 +/- 4786 (p = 0.01), and
romidepsin 4920 +/-3094 (p = 0.0003) (Fig 1A). Converting these data to percentage expres-
sion confirmed a substantial reduction in HLA class I expression compared with normal levels
(%, S.D.): 66.2+/-15.2% for vorinostat, 64.2 +/- 18% for panobinostat, and 58.5+/-11% for
romidepsin (Fig 1B). Using lower, more clinically relevant doses of vorinostat and panobino-
stat (333nM and 20nM, respectively) [7] also resulted in a significant reduction in HLA class I
expression in primary CD4 T cells (vorinostat p = 0.03, panobinostat p = 0.003) (Fig 1C) to
approximately 77.7+/- 17.5% and 74.2+/-17.2% of untreated levels respectively (Fig 1D). We
verified the results over a range of drug concentrations (S1 Fig) and confirmed the results were
not caused by cell toxicity, particularly at the clinically relevant doses where the average viabil-
ity of each of the HDACi treated cells was>93% compared to untreated controls (S1 Fig). As
this effect was demonstrated in uninfected primary cells, the mechanism was HIV-1 Nef-inde-
pendent. We therefore sought to determine the mechanism behind the lowered HLA class I
expression.
HDACi-induced HLA class I down-regulation is not due to transcriptional
blocks or HLA class I internalization
As HDACi affect transcriptional profiles, we first measured the expression of HLA class I
mRNA in HDACi treated uninfected primary cells, under the same culture conditions used
above. We found no significant difference in levels of HLA class I mRNA in cells treated with
1μM vorinostat compared to DMSO treated controls (Fig 2A). Similar results were found using
panobinostat (S2A Fig). We also measured β2 microglobulin RNA levels following HDACi
treatment–a protein that is also required for HLA class I cell surface presentation. Similar to
HLA class I RNA, we found no significant difference in β2 microglobulin levels after treatment
with vorinostat or panobinostat (Figs 2B and S2B).
Having demonstrated decreased surface protein expression of HLA class I in the absence of
a decrease in HLA Class I or β2 microglobulin mRNA levels, we tested whether HDACi led to
internalization of HLA class I. To do this, total levels of HLA Class I were assayed following
cell permeabilisation to measure both intracellular and surface amounts. All HDACi tested sig-
nificantly lowered total levels of HLA class I (vorinostat p = 0.04, panobinostat p = 0.007, romi-
depsin p = 0.02), suggesting that HDACi lead to a global reduction in HLA class I, rather than
just expression at the cell surface (Fig 2C).
To understand the relationship between intracellular and extracellular HLA Class I levels
following HDACi treatment, we conducted a time-course experiment measuring both over a
24 hour period following 1μM vorinostat treatment. Although total HLA class I levels declined
steadily over 24 hours, vorinostat led to a brief increase in extracellular levels after 4 hours of
treatment before declining again 12 hours post treatment and continuing to decline thereafter
(Fig 2D). This observed rapid effect of HDACi on HLA class I is consistent with the timing of
increased cell associated HIV-1 RNA detected in clinical studies [4]. These time-course data
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Fig 1. HDACi down-regulate HLA class I in uninfected primary CD4 T cells. A) Unstimulated CD4 T cells from eight HIV negative donors were
treated with 1uM vorinostat, 100nm panobinostat or 10nM romidepsin for 24h. Cells were stained for HLA class I. Median fluorescent intensity
(MFI) is shown (n = 8). A Friedman test with Dunn’s test for multiple comparisons was performed. B) Data from A was normalized to the MFI of the
untreated control and shown as a percentage. C) Culture of primary CD4 T cells from seven new donors was repeated using 333nM vorinostat and
20nM panobinostat (n = 7). A Friedman test with Dunn’s test for multiple comparisons was performed. D) Data from C was normalized to the MFI of
the untreated control and shown as a percent.
doi:10.1371/journal.ppat.1005782.g001
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indicate that HLA class I was not rapidly internalized after HDACi treatment as this would
have led to a decrease in extracellular levels without changing total levels of HLA class I. As the
reproducible HDACi reduction of HLA Class I was impacting total protein levels rather than
inducing internalization, we tested whether HDACi were causing enhanced proteasomal deg-
radation of HLA class I, using the proteasome inhibitors MG132 or bortezomib with or with-
out HDACi. However, all proteasome inhibitors tested down-regulated HLA class I to a greater
degree than the HDACi (S3 Fig), so any HDACi-specific inhibition could not be distinguished.
Finally, we wanted to test the duration of the HDACi effect on HLA class I levels. We treated
cells for 24 hours with HDACi and then either left them in culture with drug or washed them
three times and cultured them in media alone. Extracellular HLA class I levels were then mea-
sured. All vorinostat treated cells had normal levels of HLA class I 24 hours after washing out
the drug while panobinostat treated cells took up to 48 hours post washout for normal levels to
return (Fig 2E) suggesting a dynamic regulation of HLA class I levels rather than the sustained
level of transcription described by others [4].
Having shown HLA class I down-regulation in uninfected CD4 T cells, we turned to CD4 T
cells from HIV-1-infected individuals receiving ART.
Fig 2. Mechanism of HLA class I down-regulation. (A, B) Fold up-regulation of HLA class I and β2 microglobulin RNA, respectively, by qPCR of
DMSO and 1uM vorinostat treated samples normalized to untreated controls. All amounts were normalized to 18S copies (n = 3). A Mann-Whitney U
test used to compare levels of mRNA expression. C) MFI of total levels (after cell permeabilization) of HLA class I after 24h of culture with HDACi-free
media (n = 7), 1uM vorinostat (n = 7), 100nM panobinostat (n = 3) and 10nM romidepsin (n = 3). A Kruskal Wallis test with Dunn’s test for multiple
comparisons was performed. D) Kinetics of extracellular and total levels of HLA class I are shown. Extracellular and total values were calculated as a
percentage of their respective 0h timepoint MFI (n = 3). E) Cells were treated with 1uM vorinostat or 100nM panobinostat for 24h. Cells were then
either washed 3 times or left alone and cultured until HLA class I levels matched untreated controls. Times shown are post wash. Percent down-
regulation of HLA class I compared to untreated controls is shown for vorinostat (n = 3) and panobinostat (n = 5).
doi:10.1371/journal.ppat.1005782.g002
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HDACi down-regulate HLA class I in CD4 T cells from ART treated
patients
We isolated fresh CD4 T cells from participants (n = 8) in the HEATHER (‘HIV Reservoir Tar-
geting with Early Antiretroviral Therapy’) cohort of individuals treated with ART since pri-
mary HIV infection (PHI) (S1 Table). Cells were treated for 24 hours with 3 doses of
vorinostat, panobinostat, and romidepsin as well as the PKC activator prostratin (Fig 3). We
Fig 3. HDACi down-regulate HLA class I expression in patient samples. Fresh CD4 T cells from eight ART treated patients were
treated for 24 hours with vorinostat (1uM, 333nm and 50nM), panobinostat (100nM, 20nM, and 5nM), romidepsin (100nM, 10nM, and
5nM) or 300nM prostratin. A) Median fluorescent intensity (MFI) values after treatment with clinically relevant doses are shown. A
repeated measures one-way ANOVAwith a Greenhouse-Geisser correction with Dunnett’s multiple comparison test was performed.
B-D) MFI values reported as a percent reduction compared to untreated levels for vorinostat, panobinostat, and romidepsin dilution
series, respectively.
doi:10.1371/journal.ppat.1005782.g003
Effects of Histone Deacetylase Inhibitors on NK Cell Killing
PLOS Pathogens | DOI:10.1371/journal.ppat.1005782 August 16, 2016 6 / 22
found that clinically relevant doses of panobinostat and romidepsin significantly reduced HLA
class I levels in patient samples (p = 0.002 for both HDACi) while prostratin significantly
increased HLA class I expression (p<0.0001). Vorinostat did not significantly reduce HLA
class I expression. These results were not the result of cellular toxicity as the HDACi-treated
patient samples had similar viability to the HDACi untreated samples (S4 Fig). Of note, the
mean percent reduction of HLA class I expression in healthy controls and ART treated patients
were similar for both 20nM panobinostat (74.2% vs. 67.4% respectively) and 10nM romidepsin
(67.4% vs 60.71% respectively).
HDACi-induced HLA class I down-regulation does not significantly
impact CTL recognition
As HDACi down-regulate HLA class I in CD4 T cells, we tested whether this would impact CTL
recognition under optimised conditions. HLA class I A02 expressing CD4 T cells were infected
with HIV-1 LAI, and treated with or without 100nM panobinostat or 10nM romidepsin. We
first confirmed HDACi reduced HLA Class I expression in our in vitro infected cells (S5 Fig).
Then, infected cells were co-cultured with CD8 T cells that were transduced to express a TCR
with a high affinity for the HIV-1 Gag peptide SLYNTVATL (SL9), which is expressed on the
majority of HLA A02 infected cells [12]. HIV-1 p24 expression before and after co-culture was
assayed as a measure of CTL killing. The percentage of cells expressing p24 was reduced post
co-culture consistent with CTL targeting (Fig 4), but with no significant difference between the
untreated and the HDACi-treated CD4 T cells, and no p24 reduction when HLA A02 negative
donors were used (Fig 4B). There was no evidence for any significant effect on viability with
HDACi treatment on in vitro infected CD4 T cells (S4 Fig p>0.1), although there was donor-to-
Fig 4. HDACi do not inhibit CD4 T cell susceptibility to CTL killing. HIV-1 LAI infected CD4 T cells with or without HDACi treatment (targets) were
cultured overnight with uninfected CD4 T cells with or without HDACi treatment (non-targets) and SL9 transduced CD8 T cells (effectors) at an E:T:NT
ratio of 1:1:1. HLA class I A*02 negative donors (n = 3) were used as a control. A) Representative plots of infected CD4 T cells in the absence (left) or
presence (right) of CD8 T cells. B) Percent p24 reduction was calculated based on the percentage of p24 positive target cells before and after CD8 T
cell co-culture, using 100nM panobinostat treated targets (n = 7) and 10nM romidepsin treated targets (n = 6). Different colors represent different
donors. Separate Mann-Whitney U tests were performed.
doi:10.1371/journal.ppat.1005782.g004
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donor variation. (In particular, in two samples of the 100nM panobinostat treated cells there
was a substantial reduction in viability (~60% of untreated)). Of note, where there was variation
in target viability, this did not impact p24 reduction. Additionally, each killing assay with
HDACi had its own control where CTL were not added to control for drug toxicity.
HDACi treated CD4 T cells induce NK cell degranulation
HLA Class I down-regulation should result in increased NK cell targeting of HDACi treated
CD4 T cells. We, therefore, co-cultured primary NK cells at a 1:1 E:T ratio for 5 hours with
autologous, uninfected CD4 T cells treated or not with 100nM panobinostat and tested for NK
cell degranulation by measuring extracellular CD107a. There was significantly more NK degran-
ulation following co-culture with treated versus untreated targets (p = 0.029; untreated (%, S.D.)
1.8 +/- 0.9 vs panobinostat 4.1% +/- 0.6) (Fig 5A and 5B). This degranulation was not due to an
HDACi effect on NK cells as controls without CD4 T cell targets did not show increased
CD107a expression (Fig 5A). We tested several E:T ratios to confirm the CD4 T cells were the
cause of NK degranulation and compared the level of degranulation to co-cultures using K562
cells, which express no HLA class I, as targets (S6 Fig). NK degranulation decreased as fewer
Fig 5. HDACi treatment of CD4 T cells induces NK cell degranulation. Uninfected CD4 T cells were treated or not with HDACi for 24h and then
cultured with NK cells for 5h and stained for extracellular CD107a. A) Representative plot showing CD107a expression in NK cells alone, NK cells
treated with 100nM panobinostat for 5h, untreated NK cells co-cultured with CD4 T cells at a 1:1 ratio and untreated NK cells co-cultured with 100nM
panobinostat treated CD4 T cells at a 1:1 ratio. B) Mean of four experiments. A Mann-Whitney U test was used. C) CD4 T cells were treated with 20nM
panobinostat and 10nM romidepsin and co-cultured with NK cells as in A (n = 9). A Friedman’s test with Dunn’s test for multiple comparisons was
performed. D) NK cells were co-cultured with untreated CD4 T or CD4 T cells treated with 333nM vorinostat, 20nM panobinostat, or 10nM romidepsin
in the presence of 10μg/mL brefeldin A and cells were intracellularly stained with antibodies against IFN-γ.
doi:10.1371/journal.ppat.1005782.g005
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CD4 T cells were added, and co-culture with K562 cells led to more degranulation than with
HDACi treated CD4 T cells (S6D Fig), consistent with residual HLA class I expression on CD4
T cells after HDACi treatment. We repeated the co-culture experiments using several doses of
vorinostat, panobinostat, and romidepsin (S6A–S6C Fig) including 20nM panobinostat and
10nM romidepsin, which also led to significantly more NK cell degranulation (p = 0.01 panobi-
nostat, p = 0.0005 romidepsin) (Fig 5C). Only the highest vorinostat dose showed a similar
increase in degranulation while the clinically relevant doses did not (S6A Fig). In addition to
degranulation, NK cells cultured with HDACi treated CD4 T cells showed increased IFN-γ and
TNF-α production, compared with almost no detectable cytokine levels (similar to levels of NK
cells alone) when cultured with untreated CD4 T cells (Figs 5D and S6E).
HDACi increase the susceptibility of CD4 T cells to NK killing
As HDACi treatment of CD4 T cells led to increased NK degranulation and cytokine produc-
tion, we tested whether this translated into increased target killing. CD4 T cells infected with
HIV-1 LAI were cultured with or without 100nM panobinostat for 24 hours, at 48 hours post
infection. We then co-cultured these infected targets overnight with non-target uninfected CD4
T cells (NT) with or without NK effectors at an E:T:NT ratio of 10:1:1 and measured HIV-1 p24
expression (Fig 6A). There was a significantly larger reduction in p24 expression in infected
CD4 T cells treated with panobinostat than those without HDACi treatment (p = 0.03, Fig 6A).
As NK cells might inhibit p24 expression without killing infected cells [13], we confirmed
that the reduction in p24 reflected actual killing of infected targets by performing a FATAL
assay, as previously described [14] (Fig 6B and 6C). Briefly, infected targets were stained with a
Cell Trace Violet (CTV) dye while non-target cells were stained with a Cell Trace CFSE dye. The
ratio of targets to non-targets with and without NK cells was calculated, and the change in this
ratio after NK co-culture was converted to percentage killing. NK cells preferentially targeted
and killed infected cells, evidenced by a lower target to non-target ratio after NK cell co-culture
(Fig 6B and 6C). A significantly larger fraction of infected cells were cleared following treatment
with 100nM and 20nM panobinostat (p = 0.014, Fig 6C and p = 0.03, Fig 6D, respectively) and
10nM romidepsin (p = 0.01 Fig 6D), compared to untreated controls, but not with vorinostat.
Increased target killing was unlikely to be due to increased HIV-1 production as there was no
evidence for higher levels of p24 in HDACi treated cells before NK co-culture despite higher lev-
els of HIV-1 RNA (S7 Fig), consistent with some prior work showing HDACi alone did not
induce HIV-1 expression in ex vivo stimulated patient samples [15]. We performed the same
experiments with a range of HDACi concentrations with similar results (S8 Fig).
Expression of NK activating ligands MIC A/B, ULBP1 and ULBP2 on CD4 T cells was mea-
sured to determine potential mechanisms of the preferential killing of infected cells. CD4 T
cells were isolated from healthy donors and half were infected, as above. After 48h of infection
both uninfected and infected cells were stimulated with 20nM panobinostat or 10nM romidep-
sin using untreated cells as a negative control. Cells were stained for MIC A/B, ULBP1 and
ULBP2, all ligands for the activating NKG2D receptor found on NK cells. HDACi treatment
led to increased MIC A/B expression on uninfected cells with a greater increase with HIV-1
infection (Fig 6E), although there was no difference in ULBP1 or 2 levels with or without
HDACi treatment (Fig 6F and 6G respectively) suggesting MIC A/B levels could explain the
preferential killing of infected cells through the NKG2D pathway.
HDACi inhibit NK Cell killing
The inhibitory effects of HDACi on CTL highlight the importance of examining the effects of
HDACi not only on potential targets but also on effectors [7]. We therefore examined the direct
Effects of Histone Deacetylase Inhibitors on NK Cell Killing
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effect of HDACi on NK function, by testing the ability of 100nM panobinostat treated NK cells
to kill HDACi treated infected targets. HDACi-treated NK cells killed significantly fewer cells
than untreated NK cells [untreated (% killed, S.D.) 60.0+/- 5.8 vs panobinostat 23.4 +/- 15.5;
p = 0.029] (Fig 7A). 333nM vorinostat, 20nM panobinostat and 10nM romidepsin also reduced
NK killing, although this was only significant for the latter two (p = 0.006, p = 0.03 respectively)
(Fig 7B). We performed the same experiments using several dilutions of each HDACi with evi-
dence for a dose-related response (S9 Fig). These results were likely not due to cytotoxic effects
of HDACi as only the highest, non-physiological doses impacted cell viability (S9 Fig).
Fig 6. HDACi treatment of CD4 T cells increases NKmediated killing.HIV-1 LAI infected CD4 T cells +/- HDACi (targets) were cultured
overnight with uninfected CD4 T cells (non-targets) with or without NK cells (effectors) at an E:T:NT ratio of 10:1:1. A) CD4 T cells were treated with
100nM panobinostat and co-cultured with NK cells overnight. The percent p24 reduction with NK co-culture is shown (n = 5). A Mann-Whitney U
test was used. B) A representative FATAL assay with Cell Trace Violet (CTV) stained infected CD4 T cells (targets), CFSE stained uninfected CD4
T cells (non-targets) +/- NK cells. C) Mean of four experiments using the FATAL assay. A Mann-Whitney U test used. D) CD4 T cells were treated
with 333nM vorinostat (n = 7), 20nM panobinostat (n = 10) and 10nM romidepsin (n = 8) before culture with NK cells. Percent p24 reduction is
shown. A Kruskal-Wallis test with Dunn’s test for multiple comparisons was performed. E-G) Uninfected CD4 T cells and infected cells 48 hours
post infection were treated for 24 hours with 20nM panobinostat or 10nM romidepsin. Cells were then stained for levels of E) MICA/B, F) ULBP1,
and G) ULBP2 (n = 3).
doi:10.1371/journal.ppat.1005782.g006
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Fig 7. HDACi decrease NK function. A) NK cells treated with or without HDACi (as PBMC) for 24h (effectors) were co-cultured or not
with HIV-1 LAI-infected 100nM panobinostat treated CD4 T cells (targets) and uninfected CD4 T cells (non-targets) overnight at an E:T:
NT ratio of 10:1:1 (n = 4). Percent killing based on p24 reduction is shown and a Mann-Whitney U test was performed. B) NK cells were
treated with 333nM vorinostat (n = 7), 20nM panobinostat (n = 8) and 10nM romidepsin (n = 7). Targets were infected CD4 T cells treated
with 20nM panobinostat. A Kruskal-Wallis test with Dunn’s test for multiple comparisons was performed. C) NK cells treated with or
without 333nM vorinostat, 20nM panobinostat, or 10nM romidepsin were cultured for 5h with K562 cells at a 1:1 ratio after which
extracellular CD107a was measured (n = 8). A Friedman test with Dunn’s multiple comparison test was performed. D) A FATAL assay
was performed using NK cells treated with or without 333nM vorinostat, 20nM panobinostat, or 10nM romidepsin (effectors) which were
co-cultured with Cell Trace Violet labeled K562 cells (targets) and CFSE labeled THP1 cells (non-targets) at a 1:1:1 ratio overnight. The
ratio of targets:non-targets with and without NK cells was then used to determine percent killing (n = 3).
doi:10.1371/journal.ppat.1005782.g007
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To determine the mechanism behind the reduced killing we first measured the ability of
HDACi treated NK cells to degranulate in response to the HLA class I negative cell line K562.
We co-cultured NK cells treated or not with 333nM vorinostat, 20nM panobinostat and 10nM
romidepsin with K562 cells at a 1:1 ratio for five hours and measured extracellular CD107a
expression. Both panobinostat and romidepsin treatment resulted in significantly less degranu-
lation than untreated controls (Fig 7C p = 0.001, p = 0.003 respectively), while vorinostat
treated cells did not (Fig 7C). Experiments were repeated with a wide range of HDACi doses
and supported a dose-related response (S10 Fig). We tested whether reduced degranulation
resulted in less killing of K562 cells, using the FATAL assay with K562 as targets, THP1 cells as
non-targets and NK cells treated with or without 333nM vorinostat, 20nM panobinostat, or
10nM romidepsin as effectors. HDACi that resulted in less degranulation also resulted in less
killing of K562 cells (Fig 7D).
To understand if HDACi might phenotypically alter NK cells, making them less effective
killers, we began by examining CD16 which is associated with cytotoxicity [16]. 100nM pano-
binostat significantly reduced CD16 expression (p = 0.01) while lower doses of panobinostat
and romidepsin did not (S11A Fig). We also examined expression of the NK activating recep-
tors NKp46 and NKG2D. Similar to CD16 expression, only 100nM panobinostat significantly
reduced NKp46 expression (p = 0.0002, S11B Fig). However, both doses of panobinostat signif-
icantly reduced NKG2D expression (p = 0.001, p = 0.04; S11C Fig) while romidepsin did not,
suggesting that different HDACi can have different effects on NK phenotype while still inhibit-
ing NK function.
Variable outcomes following HDACi treatment of both infected CD4 T
cells and NK cells
As HDACi directly inhibited NK cell function, but also rendered HIV-1-infected CD4 T cells
more susceptible to killing, we wanted to determine the overall effect when both were treated.
For five individual donors, we treated either both or neither CD4 T and NK cells with 20nM
panobinostat. Overall, there was no significant difference in killing between the two, suggesting
the negative effects of treating NK cells with HDACi cancelled out any benefits of treating tar-
gets cells with panobinostat (p = 0.95 Fig 8A). However, there was donor-to-donor variation:
two of five donors showed higher levels of killing, two showed reduced killing and one donor
showed no difference. To determine if this result was drug or dose dependent, the experiment
was repeated with a further five donors using two doses of vorinostat (333nM and 50nM),
panobinostat (20nM and 5nM), and romidepsin (10nM and 5nM) as well as 300nM prostratin.
Prostratin significantly enhanced NK killing (p = 0.005) despite significant effects on cell viabil-
ity (S9G Fig), while there was weak evidence for both 10nM and 5nM doses of romidepsin
enhancing killing (p = 0.08 and p = 0.1 respectively) (Fig 8B). Interestingly, for both vorinostat
and panobinostat there was again evidence for donor-donor variation while romidepsin
showed no such variation (Fig 8B). Overall, these data suggest that different HDACi have var-
ied effects on NK mediated killing when both effectors and targets are treated, but that romi-
depsin may allow more effective NK-directed clearance of the HIV-1 reservoir.
Discussion
In this study we examined the effects of HDACi on HLA class I expression and the impact on
CTL and NK cell targeting. We found that all tested HDACi (vorinostat, panobinostat, and
romidepsin) down-regulated HLA class I expression in a Nef-independent manner. Although
HLA class I down-regulation did not significantly impact CTL recognition, it did lead to
increased NK degranulation upon co-culture and significantly increased NK cell mediated
Effects of Histone Deacetylase Inhibitors on NK Cell Killing
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Fig 8. Effects of treating both CD4 T cells and NK cells with HDACi depends on the chosen HDACi. A)
An NK co-culture assay was performed overnight at a 10:1:1 E:T:NT ratio with either infected, untreated CD4
T (targets) and untreated NK cells (effectors) or with 20nM panobinostat treated targets and HDACi treated
effectors. Intracellular p24 was measured and compared between the samples with and without NK cells. The
difference in p24 expression was then converted to percent killing as described. AWilcoxon matched-pairs
signed rank test was performed (n = 5). In B, a similar co-culture assay was performed using 2 doses of
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killing of targets. However, when NK cells were treated with HDACi their killing capacity was
reduced. Overall, our results provide insights into the use and pitfalls of NK cells as potential
effectors in HDACi based ‘kick and kill’ approaches.
It was surprising that all HDACi tested down-regulated HLA class I as previous studies
have found HDACi can up-regulate HLA class I and II molecules on tumour cells and cell lines
[9, 17]. However, these studies were not performed using healthy CD4 T cells, and it is possible
that HDACi have different effects depending on cell type and health. While HLA class I down-
regulation was HIV-1 independent, it is possible that this could lead to preferential targeting of
HIV-1 infected cells as NK cell targeting is dictated by a balance of activating and inhibitory
signals [18], which may themselves be impacted by HIV-1. Our data showing enhanced MIC
A/B expression in infected cells treated with HDACi compared to uninfected HDACi treated
cells supports this possibility. We saw a similar reduction in HLA class I in cells from patients
on ART treated ex vivo with panobinostat and romidepsin. Importantly, the transitory nature
of the down-regulation may minimize the potential negative consequences of lower levels of
HLA class I in patients.
HLA class I down-regulation led us to examine the effects of HDACi on CTL and NK tar-
geting of infected cells. Prior work showed HDACi limited CTL function in vitro upon treat-
ment of CD8 T cells with HDACi [7]. Here, we tested whether HLA class I down-regulation
upon HDACi treatment of infected targets might also affect CTL recognition. We found no sig-
nificant difference in CTL recognition of HDACi treated targets suggesting lower HLA class I
levels might not affect CTL clearance to a substantial degree. However, our studies utilized a
high affinity SL9 TCR [12] that might not be as impacted by lower levels of HLA class I expres-
sion as other TCRs.
As the effects of HDACi on both targets and effectors will impact clearance of HIV-1
infected cells, we examined how HDACi affected both CD4 T cells and NK cells, respectively.
Interestingly, HDACi treatment on these two cell types had opposite effects on HIV-1 clear-
ance. CD4 T cells (targets) treated with HDACi were more likely to be cleared than untreated
cells. Increased clearance could be due to a combination of factors including lower HLA class I
levels and higher levels of NK activating ligands such as MIC A/B. Previous data have shown
increased levels of soluble MIC A during HIV-1 infection [19] as well as reduced levels of MIC
A on the surface of CD4 T cells in HIV-1 infected patients [20, 21] possibly due to MIC A/B
shedding by HIV-1 infected cells [19, 22]. Higher MIC A/B levels caused by HDACi thus
might allow killing through MIC mediated pathways. While work has shown the importance
of ULBP1 and ULBP2 in NK mediated killing of HIV-1 infected cells [21] we found no signifi-
cant difference in their expression after HDACi treatment. HDACi treatment of NK cells (the
effectors), on the other hand, reduced HIV-1 clearance. This might be due to reduced degranu-
lation or changes to NK phenotype such NKp46, NKG2D and CD16 expression.
We found that different HDACi had varying effects on NK cell phenotype. Both high and
low doses of panobinostat reduced NKG2D expression on NK cells, but romidepsin did not.
This may be due to the fact that panobinostat is a pan-HDAC inhibitor while romidepsin
potently inhibits HDAC 1 and HDAC 2. Despite this differential effect on NK phenotype, both
romidepsin and panobinostat treatment of NK cells reduced HIV-1 clearance. This suggests
that reduced levels of degranulation may have played a larger role than NKG2D levels in reduc-
ing NK mediated killing.
vorinostat (333nM and 50nM), 2 doses of panobinostat (20nM and 5nM), 2 doses of romidepsin (10nM and
5nM) and 300nM prostratin. A Friedman test with Dunn’s multiple comparison test was performed (n = 5).
Different colors represent different donors.
doi:10.1371/journal.ppat.1005782.g008
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As HDACi impact effectors and targets differently, it was important to know whether treat-
ing both would lead to increased or decreased killing. Treating both had variable effects
depending on the HDACi used—vorinostat and panobinostat showed donor-donor variation
but romidepsin trended towards increased clearance of infected cells with all five donors show-
ing increased NK mediated killing. Previous studies using tumour cells as targets also found
treating NK cells with HDACi may decrease their function [23]. However, prior work showed
that treating both cancer cells and NK cells with HDACi still led to enhanced tumor cell killing
[24, 25]. It is therefore important to examine this balancing act in the appropriate system, due
to inherent differences in cancer and HIV-1-infected cells.
All of our experiments were performed in vitro or ex vivo. The effects of HDACi on NK or
CTL targeting/function in vivo are still unknown, although analyses of clinical trials currently
underway (e.g the RIVER study [26]) will shed light on this. While the limited dosing schedule
and half-life of the HDACi in vivomay limit effects on the immune system, the short duration
of HLA class I down-regulation after removal of HDACi may make it difficult to take advan-
tage of the enhanced susceptibility of HDACi treated CD4 T cells to NK clearance.
In summary, our experiments reaffirm the importance of studying the effects of latency
reversing agents (LRA) on multiple components of the immune response including targets and
multiple effectors in a complex system where several cell types interact. Overall, in the search
for an effective method to target the HIV-1 reservoir, our data suggest that HDACi alone will
not be effective within a ‘kick and kill’ strategy, but that other co-administered agents are likely
to be required to enhance efficacy or negate any inhibitory effects.
Materials and Methods
Ethics statement
Primary human CD4 T cells used in this study were isolated from leukocyte cones obtained
through anonymous donation to NHS Blood and Transplant (UK) after informed, written con-
sent and approval by NHS Blood and Transplant and the National Research Ethics Service
Oxfordshire Research Ethics Committee.
The HEATHER (‘HIV Reservoir targeting with Early Antiretroviral Therapy’) study was
approved by the West Midlands—South Birmingham Research Ethics Committee reference
14/WM/1104. Ethical approvals include use of samples for the studies described. All samples
were analysed anonymously.
Cell culture
CD4 T cells were negatively selected from PBMC using the EasySEP human CD4 T cell enrich-
ment kit (StemCell Technologies) per the manufacturer’s protocol. Cells were then cultured in
RPMI containing 10%FCS, penicillin/streptomycin and L-glutamine (R10). HDACi treated
cells were cultured in 1μM or 333nM vorinostat (Sigma), 100nM or 20nM panobinostat (Cam-
bridge Bioscience), or 10nM romidepsin (Abcam).
Drug doses
For vorinostat (Sigma), we chose a range of 50nM– 1 μM. The high dose of 1μMwas chosen as
it was used in in vitro latency experiments and the peak serum concentration of vorinostat in
vivo was reported to be 1.2μM; however as the free concentration of vorinostat was only
360nM [27], we used 333nM as our physiologically relevant dose. For panobinostat (Cam-
bridge Bioscience), we chose a range from 5-100nM. The mean clinical Cmax of panobinostat at
the 20mg p.o. dosing of the CLEAR trial is 40nM [28]and the steady-state plasma
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concentration is 15-22nM [7] so we chose 20nM as our physiological dose. For romidepsin
(Abcam), we chose a range of 5-100nM to match our panobinostat range. The peak serum con-
centration for clinical doses is 698nM with free drug concentration being 56nM [27]. We thus
chose 10nM, which incorporated our cell line toxicity studies. We used 300nM prostratin
based on other ex vivo studies [29].
HIV-1 infection
MT4 cells were transfected with a HIV-1 LAI encoding plasmid via electroporation. Viral
supernatant was then harvested 9 days post transfection. Isolated CD4 T cells were spinocu-
lated with this LAI supernatant (100μL per 1e6 cells, MOI 1.8) for 2 hours at 1200xg as in [30].
Cells were then washed twice with R10, resuspended and cultured in R10 with 1.25μM saquina-
vir. If infected cells were treated with HDACi, drugs were added 48 hours post infection and
left in culture for 24 hours.
HLA class I staining
CD4 T cells treated or not with HDACi were stained first with the LIVE/DEAD fixable near-IR
dead cell stain kit (Life Technologies) as per the manufacturer’s protocol along with HLA class
I staining using a HLA-ABC clone w6/32 APC antibody (eBioscience). For intracellular stain-
ing (total HLA class I), cells were stained with live/dead stain as above and then fixed with 2%
paraformaldehyde for 30 minutes. Cells were then washed and then simultaneously permeabi-
lized with 0.05% saponin and stained with HLA-ABC APC for 40 minutes. For the time-course
experiment, untreated and HDACi treated cells were stained for extracellular and total HLA
class I at t = 0, 4, 6, 8, 12, 18, and 24 hours post HDACi treatment.
RNA expression
CD4 T cells were cultured in R10, treated with DMSO or treated with HDACi as above. RNA
was isolated using the RNeasy Mini Kit (Qiagen). HLA class I RNA was measured using previ-
ously described primers 5’-CCTACGACGGCAAGGATTAC-3’ and 5’-TGCCAGGTCAGT
GTGATCTC-3’ [31]. B2 microglobulin was measured using the forward primer 5’-TCAAT
GTCGGATGGATGAAA and the reverse primer 5’-GTGCTCGCGCTACTCTCTCT [32].
Expression levels were then normalized to 18s rRNA levels measured using the previously
described primers 5’TCGAGGCCCTGTAATTGGAA-3’ and 5’GAGTCCTGCGTCGAGA
GAGC [33]. All qPCR reactions were performed with a Roche Lightcycler 480 using the Light-
cycler 480 SYBR Green I Master Mix (Roche) using the following program: 1 cycle of 95°C for
10 minutes followed by 45 cycles of 95°C for 10 seconds, 55°C for 25 seconds, and 72°C for 30
seconds.
CTL assay
HLA Class I A02 positive CD4 T cells were infected and treated or not with 100nM panobino-
stat and 10nM romidepsin as above. HLA A02 negative donors were used as a control. CD8 T
cells transduced with TCRs recognizing the HIV-1 SL9 gag peptide were supplied by Adaptim-
mune. Infected CD4 T cells were stained using the Cell Trace Violet Cell Proliferation Kit (Life
Technologies) as per the manufacturer’s protocol. Non-target uninfected CD4 T cells were
stained using the Cell Trace CFSE Cell Proliferation Kit (Life Technologies) per the manufac-
turer’s protocol. CD8 T cells were then co-cultured overnight with targets and non-targets at a
E:T:NT ratio of 1:1:1. To measure p24, cells were fixed and permeabilized (as above) and
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stained using the KC57 PE antibody (Beckman Coulter). p24 expression was then measured in
target cells.
NK cell isolation and HDACi treatment
PBMC were cultured for 24 hours in R10 with or without HDACi. NK cells were then nega-
tively selected using the EasySep Human NK Cell Enrichment Kit (StemCell Technologies) as
per the manufacturer’s protocol.
NK degranulation assay
Uninfected CD4 T cells were isolated as above and treated or not with HDACi at the indicated
doses. Meanwhile NK cells were isolated as above. NK and CD4 T cells were cultured at a 1:1,
1:0.2, or 1:0.01 ratio for 5 hours at 37°C in the presence of an anti-CD107a PE-Cy7 antibody
(Biolegend). Experiments using K562 cells were performed at a 1:1 ratio for 5 hours as with
CD4 T cells. For both CD4 T and K562 experiments, cells were then washed and stained with a
panel of: LIVE/DEAD fixable near-IR dead cell stain kit (Life Technologies), anti-CD3
eflour450 (eBioscience), anti-CD56 APC (Miltenyi), anti-CD16 FITC (Biolegend), anti-CD14
APC-Cy7 (Biolegend), anti-CD19 APC Cy7 (Biolegend). NK cells were gated on APC Cy7 neg-
ative cells (live, CD14-, CD19-), CD3 negative, CD56 positive cells.
NK cytokine assay
Uninfected CD4 T cells were isolated as above and treated or not with 333nM vorinostat,
20nM panobinostat or 10nM romidepsin. Meanwhile NK cells were isolated as above. NK and
CD4 T cells were cultured at a 1:1 ratio for 5 hours at 37°C. After the first hour of incubation
10μM brefeldin A (Sigma Aldrich) was added to all cells. After the 5 hour incubation cells were
extracellularly stained for CD3 and CD56 as above and intracellularly stained with IFN-γ
PE-Cy7 and TNF-α PerCP-Cy5.5.
NK cell p24 reduction and FATAL assay
CD4 T cells were isolated as above. Half of the cells (targets) were infected with HIV-1 as
above. The other half was cultured in R10 (non-targets). 48h post infection, infected cells were
treated or not with 100nM panobinostat, 20nM panobinostat, or 10nM romidepsin for 24h.
Meanwhile NK cells were isolated as above. 72h post infection targets were stained using the
Cell Trace Violet Cell Proliferation Kit (Life Technologies) as per the manufacturer’s protocol.
Non-targets were stained using the Cell Trace CFSE Cell Proliferation Kit (Life Technologies)
per the manufacturer’s protocol. NK cells were then co-cultured overnight with targets and
non-targets at a E:T:NT ratio of 10:1:1. In control wells NK cells were not added. After co-cul-
ture, cells were stained with LIVE/DEAD fixable near-IR dead cell stain kit (Life Technologies).
p24 was measured as above. For the FATAL assay, live cells were gated for targets and non-tar-
gets. The number of non-targets:targets (using cell counts from FlowJo) in the wells without
NK cells was converted to a NT:T ratio. This ratio was then used to predict the number of tar-
gets expected in the wells with NK cells based on their non-target number. The difference
between the actual and expected number of targets was then converted into a percent targets
killed (% cytotoxicity). For FATAL assays using K562 cells the experiments were performed as
above with K562 cells as the targets and THP1 cells as the non-targets and were done using a
1:1:1: E:T:NT ratio overnight.
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MIC and ULBP staining
CD4 T cells were isolated as above. One fraction of cells was infected HIV as above for 48
hours in the presence of saquinavir while the second fraction of cells was left uninfected in cul-
ture. After 48 hours, both uninfected and infected cells were treated with or without 20nM
panobinostat or 10nM romidepsin after which they were stained with one of two antibody
cocktails: 1) LIVE/DEAD fixable near-IR dead stain (Life Technologies) and MIC A/B PE (BD
Biosciences) 2) LIVE/DEAD ULBP1 PE (R&D Systems) and ULBP2 FITC (Biorbyt). Antibody
function was confirmed in Jurkat cells.
HDACi and NK phenotyping
PBMC were cultured for 24h in the absence or presence of 100nM panobinostat, 20nM panobi-
nostat, or 10nM romidepsin. After culture, wells were stained with a panel of: LIVE/DEAD fix-
able near-IR dead cell stain kit (Life Technologies), anti-CD3 eflour450 (eBioscience), anti-
CD16 APC (Cambridge Bioscience), anti-CD56 FITC (Cambridge Bioscience), anti-CD14
APC-Cy7 (Biolegend), anti-CD19 APC Cy7 (Biolegend), NKG2D PECy7 (Cambridge Biosci-
ence), and CD335 (NKp46) PE (Miltenyi Biotec). NK cells were gated on APC Cy7 negative
cells (live, CD14-, CD19), CD3 negative, CD56 positive cells.
Statistics
All statistical tests were performed using GraphPad Prism 6 (GraphPad Sofware, Inc.).
Supporting Information
S1 Fig. Dilution series of HLA class I and viability of HDACi treated uninfected cells. Unin-
fected CD4 T cells were treated for 24 hours with the indicated dose of HDACi. The MFI of
HLA class I as a percent of untreated controls is shown for a range of doses of vorinostat (A),
panobinostat (C), and romidepsin (E). The viability of these cells is shown in B, D, and F
respectively (n = 5)
(TIF)
S2 Fig. Panobinostat effect on HLA class I and β2-microglobulin RNA. Fold upregulation of
HLA class I (A) and β2-microglobulin RNA (B) by qPCR of DMSO and 100nM panobinostat
treated samples normalized to untreated controls is shown. All amounts were normalized to
18S copies (n = 2).
(TIF)
S3 Fig. Proteasome inhibitors reduce HLA class I levels.Healthy primary CD4 T cells were
cultured in media (untreated) or treated with 1μM vorinostat, 10μMMG132, 1μMMG132,
1μM bortezomib, or 100nM bortezomib. The MFI of HLA class I levels is shown (n = 3 vorino-
stat, MG132; n = 2 bortezomib)
(TIF)
S4 Fig. Viability of infected CD4 T cells treated with HDACi. The viability of CD4 T cells
from HIV infected patients treated with doses of vorinostat, panobinostat, romidepsin and
prostratin is shown in A-D respectively (n = 5). The viability of in vitro infected cells treated
with the same drug doses are shown in E-G (n = 3 vorinostat, prostratin; n = 6 panobinostat;
n = 5 romidepsin).
(TIF)
S5 Fig. HDACi down-regulate HLA Class I in in vitro infected CD4 T cells. CD4 T cells
were spinoculated with HIV-1 LAI for 48 hours and then treated with 100nM panobinostat or
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10nM romidepin for 24 hours. HLA Class I levels were then measured and reported as a per-
cent of untreated controls (n = 4).
(TIFF)
S6 Fig. NK degranulation at different HDACi doses and E:T ratios and TNF-α production
upon co-culture. CD4 T cells treated with several doses of vorinostat, panobinostat and romi-
depsin were co-cultured with NK cells at a 1:1 ratio for 5 hours and CD107a expression was
measured in A-C respectively (n = 4). In D, either CD4 T cells treated with or without 100nM
panobinostat or untreated K562 cells were co-cultured with NK cells at a 1:1, 1:0.2, or 1:0.1 E:T
ratio (n = 3). E) TNF-α production was measured in NK cells co-cultured for 5 hours with cells
treated with or without 333nM vorinostat, 20nM panobinostat, or 10nM romidepsin (n = 3).
(TIF)
S7 Fig. p24 and RNA levels in HDACi treated cells. CD4 T cells were infected with LAI for
48 hours after which they were either left in media or treated for 24 hours with 1μM vorinostat
or 100nM panobinostat. Intracellular p24 levels (A) and cell- associated unspliced HIV-RNA
(B) were measured 72 hours post infection (n = 4). C) Cells were infected as above and treated
with 333nM vorinostat, 20nM panobinostat, and 10nM romidepsin for 24 hours. Intracellular
p24 levels are shown (n = 5)
(TIF)
S8 Fig. HDACi increase CD4 T cell susceptibility to NK mediated killing at several drug
doses. In vitro infected CD4 T cells were treated for 24h with several doses of vorinostat, pano-
binostat, and romidepsin in A-C respectively and a killing assay based on p24 reduction was
performed as in Fig 6 (n = 3).
(TIF)
S9 Fig. Effects of various doses of HDACi treatment of NK cells on NKmediated killing
and NK cell viability.NK cells treated with or without several doses of vorinostat, panobino-
stat, and romidepsin were co-cultured with infected CD4 T cells and a killing assay based on
p24 reduction was performed as described (A, C, and E respectively, n = 3). Viability of the NK
cells was measured in B, D, and F for the same HDACi doses (n = 5). In G, viability of NK cells
treated with 300nM prostratin was measured (n = 5).
(TIF)
S10 Fig. Effects of several doses of HDACi on the degranulation of NK cells co-cultured
with K562 cells. NK cells were treated with various of doses of vorinostat, panobinostat, and
romidepsin (A-C respectively) and co-cultured or not with K562 cells for 5 hours at a 1:1 ratio.
CD107a expression was measured (n = 5).
(TIF)
S11 Fig. Effects of HDACi on NK phenotype. PBMC were cultured with or without 100nM
panobinostat, 20nM panobinostat, or 10nM romidepsin for 24h. NK cells were gated using
live/dead and lineage markers. The percentage of CD16hi (A) NKp46 (B) and NKG2D (C)
expressing cells is shown (n = 6). A Friedman test with Dunn’s test for multiple comparisons
was performed.
(TIF)
S1 Table. Patient characteristics. Patient characteristics of the eight HEATHER patients used
for HLA Class I measurements.
(PDF)
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